DXC earnings ahead amid $2.4 billion insurance unit sale talks

DXC is expected to report fiscal Q2 EPS of $0.55, down 34.7% year over year, and revenue of $2.98 billion, down 5.7%; EPS would rise 37% sequentially from $0.40. Advanced talks to sell its insurance software unit to Eldridge for about $2.4 billion dominate the outlook; the unit generated roughly $1.3 billion in trailing-12-month revenue and 10% adjusted operating margin. Analysts’ average $11.21 price target implies 30% downside from $16.09, while investors await details on the deal and whether DXC can stabilize its contracting core IT services business.

Analysis

DXC’s asset-sale story may be masking the more important question: what earnings power remains after the unit is removed? On the disclosed figures, the roughly $2.4B consideration is about 18.5x the unit’s adjusted operating income, a potentially attractive headline multiple—but not enough to establish value creation without the deal’s cash/debt treatment, taxes, stranded costs, and proceeds allocation. If DXC sells and returns capital while the core continues shrinking, near-term EPS optics could improve while the business’s durable value deteriorates.

The immediate catalyst is management’s post-close commentary: investors need a credible bridge from ongoing revenue contraction to stable margins and cash generation, not just sequential EPS improvement. Over 1–3 months, deal certainty and use of proceeds can support the shares; delay, adverse structure, or buybacks at elevated prices would weaken that support. Over 6–18 months, the key test is whether reinvestment in automation offsets erosion in legacy services. A possible take-private narrative is optionality, not an underwritable base case absent evidence of a process.

Contrarian read: the rally may have capitalized much of the sale upside while the core-business risk remains underpriced. But a clean sale with debt reduction and improving core margins would invalidate the bearish setup. Watch organic revenue, segment margins, free cash flow, deal terms, and any guidance revision.

Key Decisions for Investors

• Avoid chasing DXC ahead of the report; the asset-sale narrative creates binary after-hours risk, while the core operating trend remains unproven.
• If management cuts core outlook, free-cash-flow conversion weakens, or deal terms disappoint, consider a defined-risk DXC put spread after checking implied volatility; cap premium at risk. A confirmed transaction with credible debt reduction and stable core margins would argue against the downside trade.
• Treat any take-private speculation as a watch item, not a catalyst to price in. Verify transaction structure, taxes, stranded costs, and whether proceeds go to debt reduction, buybacks, or reinvestment before revising the valuation thesis.
• Falsification: sustained improvement in core organic revenue and margins alongside firm free cash flow and a completed sale on favorable terms would undermine the cautious view.